Clinical Trial Update: Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes an autologous CD19-directed CAR-T cell therapy for recurrent or refractory B-cell leukemia in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia

Drugs mentioned

• Autologous CD19-directed CAR-T cells (CAR-T cells targeting CD19)

Snippet

Sponsor: Second Military Medical University | Conditions: Recurrent B-Cell Tumor, Refractory B-Cell Tumor | Phase 1, Phase 2 | Status: UNKNOWN